Click Here To Find Out More About:
Submitted by: P Nagpal Nagpal
Combination Therapy
Combination therapy may benefit patients with specific genetic subtype of non-small cell lung cancer, study finds
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell. The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce longer remissions.
One of the triggers for resistance, the researchers found, is HGF, a ligand or “hook” that activates the MET protein.
When activated, HGF works through two entirely different channels to produce drug resistance, the authors report. First, it can generate cell-growth signals through a protein called GAB1. Second, it expands the number of MET-amplified cancer cells, ensuring they will become the dominant type in the lung tumors.
“Not only can HGF spur cell growth on its own, it can speed up the process by which MET-amplified cells emerge and take over the composition of the tumor.
Combination therapy may benefit patients with specific genetic subtype of non-small cell lung cancer, study finds
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell.
The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce longer remissions.
One of the triggers for resistance, the researchers found, is HGF, a ligand or “hook” that activates the MET protein.
In about 20 percent of NSCLC patients who are resistant to Tarceva the mechanism is amplification of MET, and in another 20 percent it may involve HGF.
The findings suggest that patients whose NSCLC tumors harbor even a few MET-amplified cells prior to treatment would benefit from drugs that specifically target those cells, in combination with a tyrosine kinase inhibitor. J nne notes that such drugs are already being studied in clinical trials.
A thorough analysis of a patient’s cancer prior to treatment can establish how it would ultimately develop resistance to therapy, allowing us to tailor treatment with greater precision to prevent resistance.
“For example, cancers found to harbor a small population of cells with pre-existing MET amplification will likely benefit from adding MET inhibitors to initial treatment. Those without such cells may not benefit, and these patients can avoid the added toxicity of MET inhibitors and instead focus on other strategies to prevent their cancers from becoming resistant.”
Please log on to :http://www.cancertreatment-wecareindia.com/treatment/chemo_therapy.html
Please log on to :http://www.cancertreatment-wecareindia.com/treatment/combination_therapy.html
Contact Email : info@cancertreatment-wecareindia.com
About the Author: Pankaj Nagpal – About the Author:Welcome to World Class Treatment and Surgery by We Care Health Services, India. Contact Us : www.indiahospital
tour.com
|| E-mail us on : info@indiahospitaltour.com || Contact Center Tel. :(+91) 9029304141. The surgery and medical treatments offered by We Care Health Services at JCI Accredited / ISO Certified Hospitals are vast and varied; ranging from Heart Surgery in India, Cardiology to Cardio Thoracic surgery, Total Knee / Hip / Ankle / Shoulder Joint Replacement Surgery in India including ACL reconstruction Surgery to Birmingham Hip Resurfacing Surgery in India , Spine Surgery in India like Discectomy / Laminectomy Surgery, Cervical Decompression to Anterior / Posterior Spinal Fusion Surgery in India, Chemotherapy, Radiotherapy, Cancer surgery, Sterotactic Radiotherapy, Autologous / Allogenic Bone Marrow Transplant Surgery to Breast Cancer treatments, Near relative Kidney Transplant Surgery to Dialysis and Kidney Biopsy, Low Cost Liver Transplants Surgery, Hysterectomy (Vaginal / Abdominal) to Ovarian Cystectomy, Hernia repair Surgery to Cholecystectomy, Advanced Neurosurgery in India, Bariatric surgery, Gastric Bypass Surgery in India, Eye Surgery in India, Cornea Transplant, Cataract Surgery to LASIK Eye care Surgery, IVF, ICSI, Egg Donor to Surrogacy, Minimally Invasive surgery or Laparoscopic Surgery to Cochlear Implants, Breast Lift / Tummy Tuck, Face Lift to Low Cost Rhinoplasty Cosmetic Surgery, multi specialty Hospitals in India offering first world treatments with board certified highly qualified medical consultants in attendance at third world prices..
Source:
isnare.com
Permanent Link:
isnare.com/?aid=1070931&ca=Wellness%2C+Fitness+and+Diet